Skip to content
OpenCapital
Get started

Sana Biotechnology SANA Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
Gilead Sciences logo
Gilead SciencesGILD
1.7×+0.5×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
6.1×+1.2×

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+54.1%
Enterprise value$904.32M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

quick assets/total current liabilities=1.3×

Based on the most recent quarter.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's quick ratio?
Sana Biotechnology (SANA) reported quick ratio of 1.3× in Q1 2026.
How has Sana Biotechnology's quick ratio changed year-over-year?
Sana Biotechnology's quick ratio decreased by 61.9% year-over-year, from 3.4× to 1.3×.
What is the long-term trend for Sana Biotechnology's quick ratio?
Over 5 years (2020 to 2025), Sana Biotechnology's quick ratio has grown at a -31.2% compound annual growth rate (CAGR), from 12.2× to 1.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.